<DOC>
	<DOCNO>NCT01160029</DOCNO>
	<brief_summary>The objective study compare rate extent absorption nateglinide 120 mg tablet ( test ) versus Starlix Â® ( reference ) , administer 1 x 120 mg tablet feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Nateglinide Tablets 120 mg Dr. Reddy 's Laboratories Limited Under Fed Condition</brief_title>
	<detailed_description>Single center , bioequivalence , open-label , randomize , 2-way crossover study . 54 + 4 healthy adult male female , smoker and/or non-smokers . Single oral dose ( 1 x 120 mg ) period washout least 7 day dos . Dosing 240 ml glucose solution ( 25 % ) .</detailed_description>
	<mesh_term>Nateglinide</mesh_term>
	<criteria>Male female , smoker nonsmoker , 18 year age old . Capable consent Subjects follow applies exclude study : Clinically significant illness within 4 week prior administration study medication . Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion Medical SubInvestigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive test hepatitis B , hepatitis C , HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg , heart rate less 50 100 bpm ) screening . BMI &gt; 30kg/m2 History significant alcohol abuse within six month prior screen visit indication regular use fourteen unit alcohol per week ( 1 Unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ) , History drug abuse use illegal drug : use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] crack ) within 1 year prior screen visit positive urine drug screen screen . History allergic reaction heparin , nateglinide , related drug . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , omeprazole ; examples inhibitor : antidepressant ( SSRI ) , cimetidine , diltiazem , macrolides , imidazole , neuroleptic , verapamil fluoroquinolones , antihistamine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior administration study medication . Clinically significant history presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug . Any clinically significant history presence clinically significant neurological , endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric , metabolic disease . Use prescription medication within 14 day prior administration study medication overthecounter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption hormonal contraceptive . Difficulty swallow study medication . Smoking 10 cigarette per day . Any food allergy , intolerance , restriction special diet , opinion Medical SubInvestigator , could contraindicate subject 's participation study . A depot injection implant drug ( hormonal contraceptive ) within 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day prior drug administration . Donation loss whole blood ( exclude volume blood drawn screening procedure study ) prior administration study medication follow : 50 mL 300 mL whole blood within 30 day , 301 mL 500 mL whole blood within 45 day , 500 mL whole blood within 56 day prior drug administration . Consumption food beverage contain grapefruit ( e.g . fresh , can , frozen ) within 7 day prior administration study medication . Patients affect Type 1 diabetes diabetic ketoacidosis ( last condition treat insulin ) . Breastfeeding . Positive serum pregnancy test screening . Female subject childbearing potential unprotected sexual intercourse nonsterile male partner within 14 day prior study drug administration . Acceptable method contraception : condom + spermicide ; diaphragm + spermicide ; intrauterine contraceptive device ( place least 4 week prior study drug administration ) ; hormonal contraceptive ( start least 4 week prior study drug administration ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2004</verification_date>
</DOC>